These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35471039)

  • 1. Reply to Shapiro, "Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing
    Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A
    Antimicrob Agents Chemother; 2022 May; 66(5):e0035322. PubMed ID: 35471039
    [No Abstract]   [Full Text] [Related]  

  • 2. Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing
    Shapiro S
    Antimicrob Agents Chemother; 2022 May; 66(5):e0029822. PubMed ID: 35471043
    [No Abstract]   [Full Text] [Related]  

  • 3. Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016-2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam.
    Belley A; Morrissey I; Hawser S; Kothari N; Knechtle P
    J Glob Antimicrob Resist; 2021 Jun; 25():93-101. PubMed ID: 33746112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sigmoid
    Knechtle P; Shapiro S; Morrissey I; De Piano C; Belley A
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0092621. PubMed ID: 34097479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing
    Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A;
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing
    Johnson A; McEntee L; Farrington N; Kolamunnage-Dona R; Franzoni S; Vezzelli A; Massimiliano M; Knechtle P; Belley A; Dane A; Drusano G; Das S; Hope W
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253209
    [No Abstract]   [Full Text] [Related]  

  • 7. Multicenter surveillance of
    Jean SS; Ko WC; Lu MC; Lee WS; Hsueh PR;
    Expert Rev Anti Infect Ther; 2022 Jun; 20(6):941-953. PubMed ID: 34933656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam.
    Belley A; Huband MD; Fedler KA; Watters AA; Flamm RK; Shapiro S; Knechtle P
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model.
    Bernhard F; Odedra R; Sordello S; Cardin R; Franzoni S; Charrier C; Belley A; Warn P; Machacek M; Knechtle P
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa.
    Isler B; Harris P; Stewart AG; Paterson DL
    J Antimicrob Chemother; 2021 Feb; 76(3):550-560. PubMed ID: 33332545
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Morrissey I; Magnet S; Hawser S; Shapiro S; Knechtle P
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae.
    Tselepis L; Langley GW; Aboklaish AF; Widlake E; Jackson DE; Walsh TR; Schofield CJ; Brem J; Tyrrell JM
    Int J Antimicrob Agents; 2020 Jul; 56(1):105925. PubMed ID: 32084512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia.
    Das S; Fitzgerald R; Ullah A; Bula M; Collins AM; Mitsi E; Reine J; Hill H; Rylance J; Ferreira DM; Tripp K; Bertasini A; Franzoni S; Massimiliano M; Lahlou O; Motta P; Barth P; Velicitat P; Knechtle P; Hope W
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three new inhibitors of class A β-lactamases evaluated by molecular docking and dynamics simulations methods: relebactam, enmetazobactam, and QPX7728.
    Saral Sariyer A
    J Mol Model; 2022 Mar; 28(4):76. PubMed ID: 35243556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in
    Kloezen W; Melchers RJ; Georgiou PC; Mouton JW; Meletiadis J
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431413
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.
    Mushtaq S; Vickers A; Doumith M; Ellington MJ; Woodford N; Livermore DM
    J Antimicrob Chemother; 2021 Jan; 76(1):160-170. PubMed ID: 33305800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
    J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
    Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
    Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.